Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have been given a consensus recommendation of “Moderate Buy” by the fifteen research firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $71.67.

A number of equities analysts recently weighed in on APLS shares. HC Wainwright lowered their price objective on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Wells Fargo & Company lowered their target price on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating on the stock in a report on Thursday, May 23rd. Wedbush increased their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. JPMorgan Chase & Co. reduced their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Robert W. Baird boosted their target price on Apellis Pharmaceuticals from $86.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the sale, the director now owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.80% of the stock is currently owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

A number of hedge funds have recently bought and sold shares of APLS. Vanguard Group Inc. increased its holdings in shares of Apellis Pharmaceuticals by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock worth $572,003,000 after buying an additional 85,701 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Apellis Pharmaceuticals by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after purchasing an additional 677,098 shares in the last quarter. Fiera Capital Corp lifted its stake in shares of Apellis Pharmaceuticals by 47.7% in the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares in the last quarter. Norges Bank purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth about $56,640,000. Finally, Charles Schwab Investment Management Inc. increased its position in Apellis Pharmaceuticals by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 904,409 shares of the company’s stock worth $54,138,000 after purchasing an additional 25,052 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $36.31 on Thursday. The company has a market capitalization of $4.42 billion, a price-to-earnings ratio of -10.49 and a beta of 0.88. Apellis Pharmaceuticals has a fifty-two week low of $33.49 and a fifty-two week high of $73.80. The firm has a 50-day simple moving average of $38.13 and a 200-day simple moving average of $44.31. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm’s revenue for the quarter was up 110.2% on a year-over-year basis. During the same period last year, the firm earned ($1.02) EPS. On average, equities research analysts anticipate that Apellis Pharmaceuticals will post -1.29 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).